药捷安康(2617.HK)上市不到3个月飙升超30倍，市值升破1600亿港元

Core Viewpoint - The stock price of the biopharmaceutical company,药捷安康-B (2617.HK), surged significantly, reaching a new high since its IPO, reflecting strong market interest and confidence in its clinical pipeline [1] Company Overview -药捷安康 is a biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases [1] - The company’s core product, Tinengotinib, is a unique MTK inhibitor in the registration clinical stage, targeting several recurrent or refractory solid tumors [1] Recent Developments - On September 10, the company announced that its core product, Tinengotinib, in combination with Fulvestrant, received clinical implicit approval from the National Medical Products Administration of China for a Phase II clinical trial targeting hormone receptor-positive (HR+) and HER2-negative or low-expressing recurrent or metastatic breast cancer [1]